{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:05:38Z","timestamp":1785186338505,"version":"3.55.0"},"reference-count":45,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,3,8]],"date-time":"2020-03-08T00:00:00Z","timestamp":1583625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Sufficient colonic absorption is necessary for all systemically acting drugs in dosage forms that release the drug in the large intestine. Preclinically, colonic absorption is often investigated using the rat single-pass intestinal perfusion model. This model can determine intestinal permeability based on luminal drug disappearance, as well as the effect of permeation enhancers on drug permeability. However, it is uncertain how accurate the rat single-pass intestinal perfusion model predicts regional intestinal permeability and absorption in human. There is also a shortage of systematic in vivo investigations of the direct effect of permeation enhancers in the small and large intestine. In this rat single-pass intestinal perfusion study, the jejunal and colonic permeability of two low permeability drugs (atenolol and enalaprilat) and two high-permeability ones (ketoprofen and metoprolol) was determined based on plasma appearance. These values were compared to already available corresponding human data from a study conducted in our lab. The colonic effect of four permeation enhancers\u2014sodium dodecyl sulfate, chitosan, ethylenediaminetetraacetic acid (EDTA), and caprate\u2014on drug permeability and transport of chromium EDTA (an established clinical marker for intestinal barrier integrity) was determined. There was no difference in jejunal and colonic permeability determined from plasma appearance data of any of the four model drugs. This questions the validity of the rat single-pass intestinal perfusion model for predicting human regional intestinal permeability. It was also shown that the effect of permeation enhancers on drug permeability in the colon was similar to previously reported data from the rat jejunum, whereas the transport of chromium EDTA was significantly higher (p &lt; 0.05) in the colon than in jejunum. Therefore, the use of permeation enhancers for increasing colonic drug permeability has greater risks than potential medical rewards, as indicated by the higher permeation of chromium EDTA compared to the drugs.<\/jats:p>","DOI":"10.3390\/pharmaceutics12030242","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T05:37:34Z","timestamp":1583732254000},"page":"242","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Regional Intestinal Drug Permeability and Effects of Permeation Enhancers in Rat"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5586-2906","authenticated-orcid":false,"given":"David","family":"Dahlgren","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Division of Biopharmaceutics, Uppsala University, 752 36 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2950-6737","authenticated-orcid":false,"given":"Maria-Jose","family":"Cano-Cebri\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, 46010 Val\u00e8ncia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Olander","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Division of Biopharmaceutics, Uppsala University, 752 36 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8962-2815","authenticated-orcid":false,"given":"Mikael","family":"Hedeland","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Analytical Pharmaceutical Chemistry, Uppsala University, 752 36 Uppsala, Sweden"},{"name":"Department of Chemistry, Environment and Feed Hygiene, National Veterinary Institute (SVA), 751 89 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Sj\u00f6blom","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Division of Physiology, Uppsala University, 752 36 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Lennern\u00e4s","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Division of Biopharmaceutics, Uppsala University, 752 36 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1023\/A:1015927004752","article-title":"Estimating human oral fraction dose absorbed: A correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds","volume":"5","author":"Amidon","year":"1988","journal-title":"Pharm. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s11095-006-9041-2","article-title":"Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model","volume":"23","author":"Cao","year":"2006","journal-title":"Pharm. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejpb.2019.07.005","article-title":"Rat intestinal drug permeability: A status report and summary of repeated determinations","volume":"142","author":"Dubbelboer","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1021\/acs.molpharmaceut.6b00514","article-title":"Regional intestinal permeability of three model drugs in human","volume":"13","author":"Dahlgren","year":"2016","journal-title":"Mol. Pharm."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejpb.2019.06.011","article-title":"Evaluation of drug permeability calculation based on luminal disappearance and plasma appearance in the rat single-pass intestinal perfusion model","volume":"142","author":"Dahlgren","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"eaar7047","DOI":"10.1126\/scitranslmed.aar7047","article-title":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jconrel.2018.08.032","article-title":"Oral peptide delivery: Translational challenges due to physiological effects","volume":"287","author":"Tyagi","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.ejps.2013.01.009","article-title":"Colonic absorption of salmon calcitonin using tetradecyl maltoside (TDM) as a permeation enhancer","volume":"48","author":"Petersen","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0168-3659(96)01582-9","article-title":"The rationale for peptide drug delivery to the colon and the potential of polymeric carriers as effective tools","volume":"46","author":"Rubinstein","year":"1997","journal-title":"J. Control. Release"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ejpb.2019.07.013","article-title":"Intestinal absorption-modifying excipients: A current update on preclinical in vivo evaluations","volume":"142","author":"Dahlgren","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Dahlgren, D., Sj\u00f6blom, M., Hedeland, M., and Lennern\u00e4s, H. (2020). The in vivo effect of transcellular permeation enhancers on the intestinal permeability of two peptide drugs enalaprilat and hexarelin. Pharmaceutics, 2.","DOI":"10.3390\/pharmaceutics12020099"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1021\/acs.molpharmaceut.7b00353","article-title":"Preclinical effect of absorption modifying excipients on rat intestinal transport of five model compounds and the intestinal barrier marker 51Cr-EDTA","volume":"14","author":"Dahlgren","year":"2017","journal-title":"Mol. Pharm."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1748-1716.1991.tb09206.x","article-title":"Characterization of 51Cr-EDTA as a marker of duodenal mucosal permeability","volume":"143","author":"Nylander","year":"1991","journal-title":"Acta Physiologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1021\/jm9810102","article-title":"Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach","volume":"41","author":"Winiwarter","year":"1998","journal-title":"J. Med. Chem."},{"key":"ref_15","first-page":"499","article-title":"The influence of caprate on rectal absorption of phenoxymethylpenicillin: Experience from an in-vivo perfusion in humans","volume":"54","author":"Gjellan","year":"2002","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"G653","DOI":"10.1152\/ajpgi.1989.257.4.G653","article-title":"Effects of hydrochloric acid on duodenal and jejunal mucosal permeability in the rat","volume":"257","author":"Nylander","year":"1989","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ejpb.2019.07.012","article-title":"Effects of absorption-modifying excipients on jejunal drug absorption in simulated fasted and fed luminal conditions","volume":"142","author":"Roos","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1021\/mp500834v","article-title":"Human in vivo regional intestinal permeability: Quantitation using site-specific drug absorption data","volume":"12","author":"Dahlgren","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1021\/acs.molpharmaceut.6b00515","article-title":"Regional intestinal permeability in dogs: Biopharmaceutical aspects for development of oral modified-release dosage forms","volume":"13","author":"Dahlgren","year":"2016","journal-title":"Mol. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1021\/acs.molpharmaceut.7b00279","article-title":"Regional intestinal permeability in rats: A comparison of methods","volume":"14","author":"Roos","year":"2017","journal-title":"Mol. Pharm."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1021\/acs.molpharmaceut.7b00294","article-title":"In Vivo Mechanisms of Intestinal Drug Absorption from Aprepitant Nanoformulations","volume":"14","author":"Roos","year":"2017","journal-title":"Mol. Pharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/BF01061689","article-title":"Formed and preformed metabolite excretion clearances in liver, a metabolite formation organ: Studies on enalapril and enalaprilat in the single-pass and recirculating perfused rat liver","volume":"21","author":"Pang","year":"1993","journal-title":"J. Pharm. Biopharm."},{"key":"ref_24","first-page":"44","article-title":"Kinetics and disposition of hexarelin, a peptidic growth hormone secretagogue, in rats","volume":"28","author":"Roumi","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ijpharm.2018.07.057","article-title":"Effect of absorption-modifying excipients, hypotonicity, and enteric neural activity in an in vivo model for small intestinal transport","volume":"549","author":"Dahlgren","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijpharm.2018.05.029","article-title":"The effects of three absorption-modifying critical excipients on the in vivo intestinal absorption of six model compounds in rats and dogs","volume":"547","author":"Dahlgren","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejpb.2018.09.001","article-title":"Time-dependent effects on small intestinal transport by absorption-modifying excipients","volume":"132","author":"Dahlgren","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_28","unstructured":"Paradissis, G.N., Garegnani, J.A., and Whaley, R.S. (1992). Extended Release Pharmaceutical Formulations. (5,133,974), U.S. Patent."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/apt.13329","article-title":"Regional gastrointestinal transit and pH studied in 215 healthy volunteers using the wireless motility capsule: Influence of age, gender, study country and testing protocol","volume":"42","author":"Wang","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/jps.24258","article-title":"Direct In Vivo Human Intestinal Permeability (Peff) Determined with Different Clinical Perfusion and Intubation Methods","volume":"104","author":"Dahlgren","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.2042-7158.1997.tb06093.x","article-title":"Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms","volume":"49","author":"Fagerholm","year":"1997","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1007\/s11095-006-0252-3","article-title":"Dog colonoscopy model for predicting human colon absorption","volume":"23","author":"Sutton","year":"2006","journal-title":"Pharm. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/jps.24447","article-title":"In situ perfusion model in rat colon for drug absorption studies: Comparison with small intestine and Caco-2 cell model","volume":"104","author":"Bermejo","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"ref_34","first-page":"361","article-title":"ICH M9 Guideline in development on Biopharmaceutics Classification System-based biowaivers: An Industrial Perspective from the IQ Consortium","volume":"17","author":"Bransford","year":"2019","journal-title":"Mol. Pharm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1529\/biophysj.105.060871","article-title":"Permeation of aromatic carboxylic acids across lipid bilayers: The pH-partition hypothesis revisited","volume":"89","author":"Thomae","year":"2005","journal-title":"Biophys. J."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Dahlgren, D., and Lennern\u00e4s, H. (2019). Intestinal Permeability and Drug Absorption: Predictive Experimental, Computational and In Vivo Approaches. Pharmaceutics, 11.","DOI":"10.3390\/pharmaceutics11080411"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1023\/A:1018968611962","article-title":"Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats","volume":"11","author":"Yamamoto","year":"1994","journal-title":"Pharm. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3109\/03639040903173580","article-title":"Evaluation of salmon calcitonin (sCT) enteric-coated capsule for enhanced absorption and GI tolerability in rats","volume":"36","author":"Wu","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijpharm.2004.12.017","article-title":"Improvement of absorption enhancing effects of n-dodecyl-\u03b2-D-maltopyranoside by its colon-specific delivery using chitosan capsules","volume":"293","author":"Fetih","year":"2005","journal-title":"Int. J. Pharm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.2042-7158.1987.tb03124.x","article-title":"Enhancement of jejunal and colonic absorption of fosfomycin by promoters in the rat","volume":"39","author":"Ishizawa","year":"1987","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ejps.2009.07.011","article-title":"Evaluation of intestinal absorption and mucosal toxicity using two promoters. II. Rat instillation and perfusion studies","volume":"38","author":"Maher","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/0378-5173(92)90107-D","article-title":"Assessment of enhancing ability of medium-chain alkyl saccharides as new absorption enhancers in rat rectum","volume":"79","author":"Murakami","year":"1992","journal-title":"Int. J. Pharm"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3109\/03639049309062992","article-title":"The effects of fatty acids and their derivatives on the intestinal absorption of insulin in rat","volume":"19","author":"Muranushi","year":"1993","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.addr.2016.06.005","article-title":"Intestinal permeation enhancers for oral peptide delivery","volume":"106","author":"Maher","year":"2016","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/12\/3\/242\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:05:12Z","timestamp":1760173512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/12\/3\/242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,8]]},"references-count":45,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["pharmaceutics12030242"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics12030242","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,8]]}}}